A randomised phase II/III trial evaluating preoperative chemoradiotherapy versus preoperative chemotherapy in patients undergoing adequate surgery for resectable gastric cancer

See ANZCTR for full trial details >

 

Trial Summary:

The purpose of this study is to investigate “liquid biopsies” as a method of evaluating RAS mutation status in patients with advanced colorectal cancer. This involves determining the accuracy of results of “liquid biopsies”, compared to genetic testing of cancer tissue. Different methods of testing “liquid biopsies” will be studied and compared. The study will also assess whether the ability of “liquid biopsies” to detect cancer gene mutations is different at different time points.

Supported By:

AGITG

Eligibility:

Patients over 18 years of age with histological diagnosis of metastatic colorectal cancer, resectable or un-resectable metastatic disease

Registration ID:

ACTRN12619001669189

Participation:

Australia

Australian Lead Group:

AGITG

Status:

Open

Activation Date:

30.11.2017

Chairs:

Niall Tebbutt

Contact:

liberate.study@sydney.edu.au